

Date: October 30, 2023

BSE Limited

Market Operations Dept.,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 532039

Dear Sir,

Sub: Outcome of the Board Meeting of Zenotech Laboratories Limited (the Company) held today i.e. October 30, 2023

With reference to the intimation of Board Meeting submitted on October 19, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. October 30, 2023 which commenced at 5:15 p.m. IST and ended at 6:45 p.m. IST.

The Board has, *inter-alia*, approved Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2023.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2023 along with the Limited Review Report of the Statutory Auditors thereon.

This is for your information and dissemination.

Thanking you,

Yours faithfully,

For **Zenotech Laboratories Limited**

(Abdul Gafoor Mohammad)

Company Secretary & Compliance Officer

ICSI Membership No.: A22331

Encl: as above

Independent Auditor's Review Report on review of Interim Financial Results

To the Board of Directors of Zenotech Laboratories Limited

1. We have reviewed the unaudited financial results ("the Statement") of **Zenotech Laboratories Limited** ("the Company") for the quarter and half year ended 30th September 2023, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

2. **Management's Responsibility**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. **Auditor's Responsibility**

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Conclusion

Based on our review conducted, as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm Registration No. 003990S/S200018

K VNSS Viswanadh

Viswanadh VNSS Kuchi

Partner

Membership No. 210789

Place: Hyderabad

Date: 30-October-2023

UDIN: 23210789B6YTCP3140



ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078

Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com

Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended 30 September 2023

(Rs in lakhs, except share and per equity share data)							
Sl. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From Operations	1,050.95	823.79	927.18	1,874.74	2,061.96	3,835.29
II	Other Operating Income	101.81	101.77	101.82	203.58	203.59	407.14
III	Other Income	19.28	20.08	64.67	39.36	69.51	108.37
IV	Total Income (I+II+III)	1,172.04	945.64	1,093.67	2,117.68	2,335.06	4,350.80
V	Expenses						
	a). Cost of materials consumed	-	-	-	-	6.08	6.08
	b). Purchase of Stock-in-Trade	-	-	-	-	-	-
	c). Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	d). Employee benefit expenses	221.76	222.87	192.17	444.63	383.84	787.61
	e). Finance costs	-	-	-	-	11.22	11.22
	f). Depreciation and amortization expense	180.67	180.10	180.53	360.77	359.13	717.27
	g). Other Expenses	379.77	335.97	336.03	715.74	665.95	1,378.39
	Total expenses	782.20	738.94	708.73	1,521.14	1,426.22	2,900.57
VI	Profit/(Loss) before exceptional items and tax (IV-V)	389.84	206.70	384.94	596.54	908.84	1,450.23
VII	Exceptional items	-	-	-	-	-	-
VIII	Profit/(Loss) before tax (VI-VII)	389.84	206.70	384.94	596.54	908.84	1,450.23
IX	Tax expense						
	a). Current Tax	-	-	-	-	-	-
	b). Deferred Tax	106.44	62.22	108.44	168.66	255.28	291.70
	Total Tax Expense (IX)	106.44	62.22	108.44	168.66	255.28	291.70
X	Profit/(Loss) for the period (VIII-IX)	283.40	144.48	276.50	427.88	653.56	1,158.53
XI	Other Comprehensive Income						
	a). Items that will not be reclassified to Profit or Loss Re - measurement of the defined benefit obligations	1.11	1.12	1.40	2.23	2.80	4.47
	b). Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	Less: Income Tax	(0.35)	(0.28)	(0.35)	(0.63)	(0.70)	(1.12)
	Total Other Comprehensive Income (a+b)	0.76	0.84	1.05	1.60	2.10	3.35
XII	Total Comprehensive Income for the period (X+/-XI)	284.16	145.32	277.55	429.48	655.65	1,161.88
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i.e. Other equity						2,123.95
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)						
	a). Basic	0.46	0.24	0.45	0.70	1.07	1.90
	a) Diluted	0.46	0.24	0.45	0.70	1.07	1.90

See accompanying notes to the financial results

ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078

Phone:+91 40 23480430 / 35 www.zenotechlab.com

Standalone Balance Sheet as at September 30, 2023

Rs in Lakhs

Particulars	As at 30 September 2023	As at 31 March 2023
	Unaudited	Audited
ASSETS		
(1) Non Current Assets		
(a) Property, Plant and Equipment	6,765.16	6,538.48
(b) Capital Work-In-Progress	95.30	497.87
(c) Financial Assets		
(i) Investments	-	-
(ii) Others	134.93	134.93
(d) Deferred Tax Assets (net)	767.10	935.76
(e) Income Tax Assets (net)	423.05	338.72
(f) Other Non-current Assets	17.63	15.06
Total Non - Current Assets	8,203.17	8,460.82
(2) Current Assets		
(a) Inventories	-	-
(b) Financial Assets		
(i) Trade Receivables	450.44	332.35
(ii) Cash and Cash Equivalents	1,530.85	1,114.24
(iii) Other financial asset	88.98	67.55
(c) Other Current Assets	101.80	112.34
Total Current Assets	2,172.07	1,626.48
TOTAL ASSETS	10,375.24	10,087.30
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	6,103.06	6,103.06
(b) Other Equity	2,554.06	2,123.95
Total Equity	8,657.12	8,227.01
LIABILITIES		
(1) Non-current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Other financial liabilities	76.79	73.24
(b) Other Non Current Liabilities	20.79	24.58
(c) Provisions	102.42	101.77
Total Non - Current Liabilities	200.00	199.59
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Trade payables		
(a) Total outstanding dues of Micro and Small Enterprises	14.20	16.72
(b) Total outstanding dues other than above	128.38	330.96
(ii) Other financial liabilities	341.25	374.10
(b) Other Current Liabilities	207.06	111.53
(c) Provisions	827.23	827.39
Total Current Liabilities	1,518.12	1,660.70
TOTAL EQUITY AND LIABILITIES	10,375.24	10,087.30

Zenotech Laboratories Limited		Rs in Lakhs	
Standalone Cash flow statement for the half year ended September 30, 2023		For Half year ended 30 September 2023	For Half year ended 30 September 2022
A. Cash flows from operating activities			
Profit/(loss) before taxation		596.54	908.84
Adjustments for:			
Depreciation and amortisation		360.77	359.13
Amounts written back		-	-
Unrealised foreign exchange loss, net		-	-
Profit on sale of Property , Plant and Equipment		-	-
Interest expenses		-	11.22
Interest income		(35.93)	(8.93)
Exceptional items		-	-
Operating cash flows before working capital changes		921.38	1,270.26
Changes in Working Capital:			
(Increase)/ decrease in trade receivables		(118.09)	111.67
(Increase)/ decrease in inventories		-	6.08
(Decrease)/ increase in trade payables		(205.10)	(66.11)
(Increase)/ decrease in other financial assets		(21.43)	(39.71)
(Increase)/ decrease in current non financial assets		-	-
(Increase)/ decrease in non-current financial assets		-	(33.21)
(Increase)/ decrease in non-current assets		-	-
(Increase)/ decrease in other current assets		10.54	(12.61)
(Decrease)/ increase in provisions for non current liabilities		2.64	9.17
(Decrease)/ increase in provisions for current liabilities		(0.16)	2.21
(Decrease)/ increase in other financial liabilities		(32.85)	(42.67)
(Decrease)/ increase in other current liabilities		95.54	74.00
Cash used in operations		652.47	1,279.07
Income taxes paid/ TDS (net)		(84.32)	(60.86)
Net cash used in operating activities (A)		568.15	1,218.21
B. Cash flows from investing activities			
Payment for Purchase of property plant equipment (Including Capital advance & Work in Progress)		(187.48)	(19.52)
Proceeds from sale of Property , Plant and Equipment		-	-
Deposits towards margin money		-	-
Interest income received		35.94	8.93
Net cash provided by/ (used in) investing activities		(151.54)	(10.59)
C. Cash flows from financing activities			
Repayment of borrowings		-	(600.00)
Interest paid		-	(11.22)
Net cash provided by financing activities (C)		-	(611.22)
Net increase/ (decrease) in cash and cash equivalents during the year(A+B+C)		416.61	596.40
Cash and cash equivalents at the beginning of the year		1,114.24	241.48
Cash and cash equivalents at the end of the year		1,530.85	837.87

Notes:

1. The above financial results for the quarter and half year ended September 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30th October, 2023 and have undergone a 'limited review' by the Statutory Auditors of the Company.
2. These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters on the results of the Company is not material.
4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8th June, 2022 and Long Form Standing certificate dated 15th June, 2022 respectively, received from the concerned authorities.

Winding up order for Zenotech Laboratories Nigeria Limited has been received during FY: 2019-20. However, related filings with RBI is pending.

Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence consolidated financial statements/Results is no longer applicable.

5. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
6. The Company has only one segment, i.e. Pharmaceuticals.
7. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board



Chairman
DIN-01219312

Place: New Delhi
Date: 30-October-2023